BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/16/2024 6:17:55 AM | Browse: 258 | Download: 842
 |
Received |
|
2024-05-02 07:06 |
|
Peer-Review Started |
|
2024-05-02 07:06 |
|
First Decision by Editorial Office Director |
|
2024-05-22 03:23 |
|
Return for Revision |
|
2024-05-22 08:45 |
|
Revised |
|
2024-06-03 07:52 |
|
Publication Fee Transferred |
|
2024-06-27 01:23 |
|
Second Decision by Editor |
|
2024-06-26 02:46 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-06-26 08:34 |
|
Articles in Press |
|
2024-06-26 08:34 |
|
Edit the Manuscript by Language Editor |
|
2024-07-03 06:08 |
|
Typeset the Manuscript |
|
2024-07-11 03:04 |
|
Publish the Manuscript Online |
|
2024-07-16 06:17 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Programmed cell death 1 inhibitor sintilimab plus concurrent chemoradiotherapy for locally advanced pancreatic adenocarcinoma
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Shi-Qiong Zhou, Peng Wan, Sen Zhang, Yuan Ren, Hong-Tao Li and Qing-Hua Ke |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Qing-Hua Ke, MM, PhD, Additional Professor, Chief Physician, Department of Chemoradiotherapy, The First Affiliated Hospital of Yangtze University, No. 40 Jinglong Road, Shashi District, Jingzhou 434000, Hubei Province, China. 3803354759@qq.com |
| Key Words |
Immunotherapy; Concurrent chemoradiotherapy; Locally advanced pancreatic adenocarcinoma; Programmed cell death 1; Sintilimab |
| Core Tip |
The article presents an insightful exploration of a study of the combination of sintilimab with S-1 and gemcitabine concurrent radiotherapy for locally advanced pancreatic cancer (LAPC). The observation group had significantly longer median progression-free survival and overall survival than the control group. The occurrence of severe adverse events did not exhibit a statistically significant difference between the observation group and the control group, with a P value greater than 0.05. It is considered a promising, effective and well-tolerated treatment for LAPC. |
| Publish Date |
2024-07-16 06:17 |
| Citation |
Zhou SQ, Wan P, Zhang S, Ren Y, Li HT, Ke QH. Programmed cell death 1 inhibitor sintilimab plus concurrent chemoradiotherapy for locally advanced pancreatic adenocarcinoma. World J Clin Oncol 2024; 15(7): 859-866 |
| URL |
https://www.wjgnet.com/2218-4333/full/v15/i7/859.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v15.i7.859 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
